AN EXTENSION STUDY TO PROVIDE BORTEZOMIB TO PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA WHO PREVIOUSLY PARTICIPATED IN A BORTEZOMIB PHASE I/II STUDY AND WHO MAY BENEFIT FROM RE-TREATMENT WITH OR CONTINUATION OF BORTEZOMIB THERAPY: